AbbVie, Jacobio to collaborate on SHP2 inhibitors

By The Science Advisory Board staff writers

June 1, 2020 -- AbbVie and Jacobio Pharmaceuticals announced they are partnering to develop and market SHP2 inhibitors, which target a node in cancer and immune cells.

Inhibition of the SHP2 protein reduces cancer cell growth and prompts antitumor immune response, according to the firms. Jacobio has developed early-clinical-stage oral small molecules called JAB-3068 and JAB-3312 that inhibit SHP2 activity.

Under terms of the deal, Jacobio will grant AbbVie exclusive license to its SHP2 portfolio. It will continue to conduct clinical trials, for which AbbVie will cover expenses.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.